TABLE 4.

In vitro susceptibilities of blood stream infection isolates of Candida spp. to fluconazole and investigational antifungal agents (SENTRY Program, 1997 to 1999)

Species (no. tested)	Antifungal agent	MIC (μg/ml) and % susceptible by year
		1997		1998		1999
		50/90%	% Sa	50/90%	% Sa	50/90%	% Sa
C. albicans (658)	Fluconazole	0.25/0.5	99	0.25/0.5	98	0.25/0.25	100
	Ravuconazole	0.007/0.03	99	0.007/0.03	99	0.007/0.015	100
	Voriconazole	0.015/0.06	98	0.007/0.03	99	0.007/0.015	100
C. glabrata (180)	Fluconazoleb	16/32	48	8/16	63	4/16	83
	Ravuconazole	0.25/1	92	0.25/1	95	0.12/1	94
	Voriconazole	0.25/1	91	0.25/1	95	0.12/0.5	96
C. parapsilosis (179)	Fluconazole	0.5/2	100	0.5/1	98	0.5/1	100
	Ravuconazole	0.015/0.06	100	0.015/0.06	100	0.015/0.06	100
	Voriconazole	0.03/0.12	100	0.015/0.06	100	0.015/0.03	100
C. tropicalis (104)	Fluconazole	1/2	100	0.5/1	100	0.5/2	97
	Ravuconazole	0.03/0.12	100	0.03/0.12	100	0.015/0.12	97
	Voriconazole	0.06/0.12	100	0.03/0.12	100	0.03/0.12	97
C. krusei (20)	Fluconazole	32/—c	0	32/—	0	16/—	0
	Ravuconazole	0.25/—	100	0.25/—	100	0.25/—	100
	Voriconazole	0.5/—	100	0.25/—	100	0.25/—	100

^a% S, percent susceptible at a MIC of ≤8 μg/ml (fluconazole) or ≤1 μg/ml (all other agents). 

^bP = 0.0004 for trend in susceptibility by year. 

^c—, MIC₉₀ not calculated because <10 isolates were identified during the year.